Daghistani Hussam, Attallah Dalya, Alqarni Mona Abdulrahman, Saleh Bandar Hasan, Alhussainy Nabeel H, Sait Ahmad M, Mufrrih Mohammed, Alhazmi Wafaa, Alharbi Ohood S, Alhazmi Khulud A, Altalhi Rawan, Halabi Waiel S, Almuhayya Sarah, Aldehalan Faye A, Altarawneh Hala, Abu Lubad Mohammad, Bani Abdel-Rahman Sulaiman M S, Alfadil Abdelbagi, Ibrahem Karem
Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Regenerative Medicine Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Infect Drug Resist. 2025 Aug 19;18:4179-4186. doi: 10.2147/IDR.S524005. eCollection 2025.
The rising global threat of antimicrobial resistance, particularly among multidrug-resistant pathogens like , has prompted research into repurposing existing drugs with established safety profiles. Cisplatin, a well-known anticancer agent, has shown preliminary antimicrobial activity but its efficacy against has not been thoroughly explored. This study aims to evaluate the antimicrobial potential of cisplatin against clinical strains of by determining the minimum inhibitory concentration (MIC).
This study assessed whether cisplatin could serve as a novel therapeutic option for treating infections caused by via broth microdilution assay, especially as the pathogen shows increasing resistance to last-resort antibiotics such as meropenem, colistin, and tigecycline. Findings from this research could contribute to expanding the arsenal of treatments for resistant infections.
The study found that 54.9% of isolates had an MIC of 16 µg/mL, 26.8% had 32 µg/mL, 12.7% had 64 µg/mL, and 5.6% had 8 µg/mL. While cisplatin demonstrated antibacterial activity, no statistically significant difference ( = 0.089) was observed between sensitive and resistant strains. A key limitation of this study is the small number of both resistant and sensitive strains, which limits statistical power. Increasing the sample size in future studies will allow for a more robust assessment of cisplatin's efficacy and validate the observed MIC similarities. Additionally, further studies including resistance assays, time-kill kinetics, and in vivo models are needed to explore its bactericidal potential and efficacy in combination with β-lactams.
Although cisplatin exhibited activity against , its clinical potential remains uncertain, and further investigation is necessary to optimize its use and overcome resistance.
全球抗菌药物耐药性的威胁日益增加，尤其是在像[病原体名称未给出]这样的多重耐药病原体中，这促使人们研究重新利用具有既定安全特性的现有药物。顺铂是一种著名的抗癌药物，已显示出初步的抗菌活性，但其对[病原体名称未给出]的疗效尚未得到充分探索。本研究旨在通过测定最低抑菌浓度（MIC）来评估顺铂对[病原体名称未给出]临床菌株的抗菌潜力。
本研究通过肉汤微量稀释法评估顺铂是否可作为治疗由[病原体名称未给出]引起的感染的新治疗选择，特别是因为该病原体对美罗培南、黏菌素和替加环素等最后手段抗生素的耐药性不断增加。这项研究的结果可能有助于扩大耐药性[病原体名称未给出]感染的治疗手段。
研究发现，54.9%的分离株MIC为16μg/mL，26.8%为32μg/mL，12.7%为64μg/mL，5.6%为8μg/mL。虽然顺铂显示出抗菌活性，但在敏感和耐药菌株之间未观察到统计学上的显著差异（P = 0.089）。本研究的一个关键局限性是耐药和敏感菌株的数量都很少，这限制了统计效力。在未来的研究中增加样本量将有助于更有力地评估顺铂的疗效，并验证观察到的MIC相似性。此外，还需要进一步的研究，包括耐药性测定、时间杀菌动力学和体内模型，以探索其杀菌潜力以及与β-内酰胺类联合使用的疗效。
虽然顺铂对[病原体名称未给出]表现出活性，但其临床潜力仍不确定，需要进一步研究以优化其使用并克服耐药性。
